{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:57Z","timestamp":1789858137381,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BMBF","award":["01GM1512D"],"award-info":[{"award-number":["01GM1512D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12969-018-0236-y","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T11:08:54Z","timestamp":1524136134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["IL-6 blockade in systemic juvenile idiopathic arthritis \u2013 achievement of inactive disease and remission (data from the German AID-registry)"],"prefix":"10.1186","volume":"16","author":[{"given":"M.","family":"Bielak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Husmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Weyandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"H\u00fcgle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Neudorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lilienthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kallinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Niehues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wittkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wei\u00dfbarth-Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Heubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lainka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"issue":"1","key":"236_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2015.04.018","volume":"159","author":"N Bruck","year":"2015","unstructured":"Bruck N, Schnabel A, Hedrich CM, et al. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (SJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159(1):72\u201383.","journal-title":"Clin Immunol"},{"issue":"1","key":"236_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/ncprheum0084","volume":"2","author":"P Woo","year":"2006","unstructured":"Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28\u201334. Review.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"7","key":"236_CR3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"236_CR4","unstructured":"Martini, A. PRINTO classification for SJIA: oral presentation: toward a new classification of JIA, in PRES annual meeting. 2016: Genoa, Italy."},{"issue":"1","key":"236_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. 2018;16(1):7. https:\/\/doi.org\/10.1186\/s12969-018-0224-2 .","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"236_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F, et al. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259\u201368.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"236_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/1744666X.2015.1032257","volume":"11","author":"A Woerner","year":"2015","unstructured":"Woerner A, von Scheven-G\u00eate A, Cimaz R, et al. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol. 2015;11(5):575\u201388.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"236_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","volume":"55","author":"S Tarp","year":"2016","unstructured":"Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669\u201379.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"236_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1759720X12455960","volume":"4","author":"S Yokota","year":"2012","unstructured":"Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387\u201397.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"236_CR10","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner H, et al. Two randomized trials of Canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"2","key":"236_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557\u201367.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"236_CR12","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"236_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/imt.15.104","volume":"8","author":"P Barone","year":"2016","unstructured":"Barone P, Pignataro R, Garozzo MT, et al. IL-6 blockers in systemic onset juvenile idiopathic arthritis. Immunotherapy. 2016;8(1):79\u201387.","journal-title":"Immunotherapy"},{"issue":"12","key":"236_CR14","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/art.39796","volume":"68","author":"J Klotsche","year":"2016","unstructured":"Klotsche J, Raab A, Niewerth M, et al. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013. Arthritis Rheumatol. 2016;68(12):3023\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"236_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/rheumatology\/keq270","volume":"50","author":"E Lainka","year":"2011","unstructured":"Lainka E, Bielak M, Hilger V, et al. Translational research network and patient registry for auto-inflammatory diseases. Rheumatology (Oxford). 2011;50(1):237\u201342.","journal-title":"Rheumatology (Oxford)"},{"key":"236_CR16","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E. Preliminary criteria remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290\u20134.","journal-title":"J Rheumatol"},{"issue":"2","key":"236_CR17","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"key":"236_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1546-0096-10-40","volume":"10","author":"S Kumar","year":"2012","unstructured":"Kumar S, Kunhiraman DS, Rajam L, et al. Application of the Yamaguchi criteria for classification of \u201csuspected\u201d systemic juvenile idiopathic arthritis (SJIA). Pediatr Rheumatol. 2012;10:40. https:\/\/doi.org\/10.1186\/1546-0096-10-40 .","journal-title":"Pediatr Rheumatol"},{"issue":"9","key":"236_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","volume":"71","author":"A Martini","year":"2012","unstructured":"Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71(9):1437\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"236_CR20","first-page":"424","volume":"19","author":"M Yamaguchi","year":"2001","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 2001;19(3):424\u201330.","journal-title":"J Rheumatol"},{"key":"236_CR21","doi-asserted-by":"publisher","DOI":"10.3205\/15dgrh156","volume-title":"Classical Hodgkin lymphoma in a 10-year-old girl with systemic-onset juvenile idiopathic arthritis under IL-6 inhibition (tocilizumab)","author":"J Forster","year":"2015","unstructured":"Forster J, Weigt-Usinger K, L\u00fccke T, et al. Classical Hodgkin lymphoma in a 10-year-old girl with systemic-onset juvenile idiopathic arthritis under IL-6 inhibition (tocilizumab); 2015. https:\/\/doi.org\/10.3205\/15dgrh156 ."},{"issue":"9","key":"236_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keu032","volume":"53","author":"J Pfeil","year":"2014","unstructured":"Pfeil J, Grulich-Henn J, Wenning D, et al. Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab. Rheumatology (Oxford). 2014;53(9):1713\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"236_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1385\/CRIAI:28:3:231","volume":"28","author":"S Yokota","year":"2005","unstructured":"Yokota S, Miyamae T, Imagawa T, et al. Clinical study of Tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28(3):231\u20138. Review.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"236_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","volume":"19","author":"G Horneff","year":"2017","unstructured":"Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256. https:\/\/doi.org\/10.1186\/s13075-017-1462-2 .","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"236_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of Tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110\u20137.","journal-title":"Ann Rheum Dis"},{"key":"236_CR26","doi-asserted-by":"publisher","unstructured":"Yokota S, Itoh Y, Morio T et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2015. doi: https:\/\/doi.org\/10.1136\/annrheumdis-2015-207818 . [Epub ahead of print]. pii: annrheumdis-2015-207818.","DOI":"10.1136\/annrheumdis-2015-207818"},{"key":"236_CR27","doi-asserted-by":"publisher","unstructured":"Woerner A, Uettwiller F, Melki I et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open 2015; 1(1):e000036. doi: https:\/\/doi.org\/10.1136\/rmdopen-2014-000036 . eCollection 2015.","DOI":"10.1136\/rmdopen-2014-000036"},{"key":"236_CR28","unstructured":"Kostik MM, Isupova EA, Chikova IA, et al. Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment. Clin Exp Rheumatol. 2017;"},{"key":"236_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0031-1275747","volume":"36","author":"P Haas","year":"2011","unstructured":"Haas P, et al. Systemic onset juvenile idiopathic arthritis \u2013 at the borderline between Autoinflammation and autoimmunity. Akt Rheumatol. 2011;36:236\u201341.","journal-title":"Akt Rheumatol"},{"key":"236_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1546-0096-12-28","volume":"12","author":"B H\u00fcgle","year":"2014","unstructured":"H\u00fcgle B, Hinze C, Lainka E, Fischer N, Haas JP. Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. Pediatr Rheumatol Online J. 2014;12:28. https:\/\/doi.org\/10.1186\/1546-0096-12-28.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"236_CR31","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.21774","volume":"54","author":"D Singh-Grewal","year":"2006","unstructured":"Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595\u2013601.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"236_CR32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/rheumatology\/kev429","volume":"55","author":"L Kearsley-Fleet","year":"2016","unstructured":"Kearsley-Fleet L, Davies R, Baildam E, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford). 2016;55(9):1556\u201365.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"236_CR33","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasigli\u00e8 D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505\u201315.","journal-title":"Arthritis Rheum"},{"key":"236_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66:1034\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"236_CR35","doi-asserted-by":"publisher","unstructured":"Sikora KA, Grom AA. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr Opin Pediatr 2011; 23(6): 640\u2013646. doi: https:\/\/doi.org\/10.1097\/MOP.0b013e32834cba24 . Review.","DOI":"10.1097\/MOP.0b013e32834cba24"},{"issue":"6","key":"236_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-013-0053-1","volume":"15","author":"JE Frampton","year":"2013","unstructured":"Frampton JE, et al. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis. Paediatr Drugs. 2013;15(6):515\u201331.","journal-title":"Paediatr Drugs"},{"issue":"7","key":"236_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","volume":"14","author":"G Horneff","year":"2015","unstructured":"Horneff G, et al. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015;14(7):1111\u201326.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"236_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1546-0096-10-30","volume":"10","author":"EA Kessler","year":"2012","unstructured":"Kessler EA, Vora SS, Verbsky JW, et al. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J. 2012;10(1):30.","journal-title":"Pediatr Rheumatol Online J"},{"key":"236_CR39","first-page":"381","volume":"5","author":"B Beutler","year":"1986","unstructured":"Beutler B, Cerami A, et al. Cahcectin tumor necrosis factor: an endgenous mediator of shock and inflammation. Immunol. 1986;5:381\u201393.","journal-title":"Immunol"},{"issue":"1","key":"236_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/0975-7406.76489","volume":"3","author":"J Jain","year":"2011","unstructured":"Jain J, Gautam V, Naseem S. Acute-phase proteins: as diagnostic tool. J Pharm Bioallied Sci. 2011;3(1):118\u201327.","journal-title":"J Pharm Bioallied Sci"},{"key":"236_CR41","first-page":"A9752","volume":"160","author":"W Opstelten","year":"2016","unstructured":"Opstelten W, Bijlsma JW, Gelinck LB, Hielkema CM, Verheij TJ, van Eden W. Impaired immunity: risk groups and consequences for general practice. Ned Tijdschr Geneeskd. 2016;160:A9752. Dutch","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"236_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","volume":"58","author":"M Shimizu","year":"2012","unstructured":"Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287\u201394. https:\/\/doi.org\/10.1016\/j.cyto.2012.02.006 . Epub 2012 Mar 6.","journal-title":"Cytokine"},{"issue":"12","key":"236_CR43","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/art.24137","volume":"58","author":"H Wittkowski","year":"2008","unstructured":"Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924\u201331.","journal-title":"Arthritis Rheum"},{"key":"236_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00112-011-2545-9","volume":"160","author":"M Frosch","year":"2012","unstructured":"Frosch M, Holzinger D, Roth J, et al. Systemic onset juvenile idiopathic arthritis. Monatschr Kinderheilkd. 2012;160:217\u201323.","journal-title":"Monatschr Kinderheilkd"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-018-0236-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:47:25Z","timestamp":1720226845000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-018-0236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1186\/s12969-018-0236-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,5]]},"assertion":[{"value":"3 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The AID-registry has been approved by the ethics committees and the data protection responsible at the University of Duisburg-Essen and Muenster, as well as the Medical Association Nordrhein in Duesseldorf. Parents, children between 9 and 13 years of age and young patients aged \u2265 14 years provide informed consent. All old and new documents of the ethic committees are saved on our homepage\n                      \n                      .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E Lainka has received consulting fees, speaking fees, and\/or honoraria from Novartis (less than $10,000 each) and research support from Sobi. J-P Haas has received research support from Novartis and Pfizer. T Kallinich has received consulting fees, speaking fees, and\/or honoraria from Bristol-Myers-Squibb, CSL, Novartis and Roche (less than $10,000 each) and research support from Novartis. E Wei\u00dfbarth-Riedel has received consulting fees, speaking fees, and\/or honoraria from Novartis (less than $10,000 each). H Wittkowski has received consulting fees, speaking fees, and\/or honoraria from Novartis (less than $10,000 each). G Horneff has received honoraria from Abbvie, Novartis, Pfizer and Roche-Chugai (less than $10,000 each) and research support from Abbvie, Novartis, Pfizer and Roche-Chugai. D Foell has received honoraria from Novartis, Pfizer, Roche-Chugai and Sobi (less than $10,000 each) and research support from Novartis and Pfizer. M Bielak, E Husmann, N Weyandt, J Klotsche, E Lilienthal, T Niehues, K Tenbrock, G Heubner, T Lutz and R Berendes do not have a competing interest. U Neudorf has received speaking fees from Pfizer, Abbvie (less than $10,000 each) und research support from Chugai (more than $10,000). B H\u00fcgle has received speaking fees and\/or honoraria from Novartis and Roche (less than $10,000 each) and two unrestricted research grants from Novartis. PT Oommen has received consulting fees, speaking fees, and\/or honoria from Novartis and CSL Behring (less than $5,000 each).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"22"}}